OBJECTIVE: Numerous reports have emphasized the need for reduction in transfusions of allogeneic red blood cells (RBC) due to increased morbidity and mortality. Nevertheless, transfusion rates are still high in several cardiac surgery institutions. Reports on longterm survival after cardiac surgery and RBC transfusion are few.
INTRODUCTION
Transfusion of allogeneic red blood cells (RBC) in patients undergoing cardiac surgery is associated with increased mortality and morbidity [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Transfusion of RBC as a risk factor for early mortality has been well established whereas the effect of RBC transfusion on late mortality is less well described. Previously published long-term survival studies are either on selected types of surgery [5, 6, 8, 9] , single centre studies [4, 5, 7, 9] or studies with a relatively short observation time [6, 8, 9] . Furthermore, in all studies that include immediate postoperative mortality and survival Kaplan-Meier plots tend to run parallel after the first month, indicating less impact on the long-term survival [4, 9, 10] . The aim of this study was to evaluate the effect of RBC transfusions on long-term survival after cardiac surgery in a historical, consecutively collected multicentre cohort. The authors hypothesized that patients receiving RBC in the peri-and postoperative phases have increased long-term mortality.
PATIENTS AND METHODS
We conducted this cohort study using population-based healthcare databases. The Danish National Health Service provides free universal tax-supported health care to the entire population, including access to surgery. We used the unique personal identifier assigned to each Danish citizen at birth to link records for individuals across the databases [11] .
Study population
To identify adult patients (age ≥15 years) who underwent cardiac surgery at four cardiac centres-Aarhus University Hospitals, Skejby and Aalborg, Odense University Hospital and Varde Heart center in the period 1 January 1999 and 30 June 2010, we used computerized data from the Western Denmark Heart Registry (WDHR), a valuable research tool providing ongoing longitudinal registration of detailed patient and procedural data [12] . WDHR is an internet-based clinical registry containing the details of all patients undergoing adult cardiac surgery in Western Denmark, covering an uptake area of 60% of Denmark. Reporting to the registry has been mandatory since 1999. Detailed patient-, EuroSCORE-, surgery-, anaesthesia-and intensive care-related data together with in-hospital postoperative complications are collected prospectively and consecutively. Data quality is ensured by automatic validation rules at data entry combined with systematic validation procedures and random spot checks of data after entry. Information regarding transfusions is registered in anaesthesia and intensive care forms. The content of the database has been updated twice, primarily by increasing the number of obligatory data, and since 2006 all data related to this study have been obligatory. Before 2006, missing data on otherwise filled forms were considered not present. Missing relevant data from forms not filled at the time of surgery were retrieved for this study. Data on missing information of transfusion of blood components were obtained from the Danish Transfusion Registry, containing all transfusion data in Denmark.
A total of 25 117 procedures were registered in the study period. Patients with multiple entries (1049) and previous cardiac surgery (985) were excluded. To reduce bias from procedure types only coronary artery bypass grafting (CABG), aortic valve replacement (AVR), mitral valve replacement (MVR) plus combinations (CABG + AVR) and (CABG + MVR) were allowed, and thus 2329 were considered not eligible for this study. As the immediate postoperative mortality is caused by a mixture of cardiac, surgical and infectious problems which blunt any impact of transfusions, patients dying within 30 days after surgery (668) were excluded, together with 85 patients with an invalid Civil Personal Registration identifier (CPR number) and therefore not eligible for follow-up leaving a basic cohort of 20 001 (Fig. 1) . The final outcome data were collected on 30 June 2011 giving an observation time between 1 and 12 years, with an average of 5.6 years.
Transfusion blood and blood products
Transfusions of allogeneic blood components such as RBC, fresh frozen plasma (FFP) and platelet (PLT) concentrates were given at the discretion of the attending anaesthesiologist and/or surgeon. No specific transfusion algorithm was used until 2004. Indications for allogeneic transfusion were based on routine laboratory measurements of International normalized ratio (INR), activated clotting time (ACT), activated partial thromboplastin time (APTT) PLT counts, fibrinogen levels, haemoglobin and haematocrit values, in addition to measurements of haemodynamic and physiological data, the rate of blood loss and the existence of concomitant diseases. Thromboelastometry-guided blood-component therapy was established in all centres in the period 2004-2008. The target of haemoglobin level tended to be higher with the increase in the age of the patient.
Perioperative procedures
According to hospital protocols, all preoperative cardiac medications were continued until the morning of surgery. Patients with acute coronary syndrome were kept on angiotensin-converting enzyme inhibitors and PLT inhibitors, including aspirin, until surgery. In general, anaesthesia was either based on intravenous Propofol or inhalation of Sevoflurane together with Fentanyl or Sufentanil and some supplemented with epidural analgesia according to hospital protocols.
In the operating room patients received routine monitoring, including five-lead electrocardiogram radial and pulmonary artery catheters with or without continuous cardiac output measurement (Swan-Ganz CCO/VIP; Edwards Lifesciences LLC, Irvine, CA, USA), pulse oximetry, capnography, urinary output and temperature monitoring. The majority of patients were also monitored by transoesophageal echocardiography.
Routine surgical and cardio-protective techniques were used, including crystalloid or cold blood cardioplegia, closed cardiopulmonary bypass systems consisting of tubing with a surfacemodifying additive coating, an arterial filter with heparin coating, a hollow fibre membrane oxygenator with a surface-modifying additive coating, and a venous and cardiotomy reservoir. Most patients were maintained normothermic or slightly hypothermic. At the conclusion of the surgical procedure, reperfusion of the heart was performed according to the general condition of the patient' and cross-clamp duration. Whether coronary artery bypass surgery (CABG) was performed on-or off-pump was left to the discretion of the surgeons. Due to blood conservation strategies, most patients received antifibrinolytics either Tranexamic acid or Aprotinin. Cell saver has rarely been used especially after 2005 in all centres. Postoperative autotransfusion of mediastinal blood was routinely used in most patients, except for one centre which abandoned this in 2007. However, this change in strategy only influenced less than 6% of evaluated patients.
Patient, procedure and outcome characteristics
Patients and procedures were characterized primarily by EuroSCORE (www.euroscore.org) and detailed procedure types supplemented with re-do bleeding, postoperative dialysis, perioperative use of inotropics and myocardial infarction (MI).
The primary outcome was all-cause death any time occurring during the observation period. Data on mortality were obtained from the Danish Civil Registration System, which keeps daily updated records of the entire Danish population on vital status, date of death, residence, and migration since 1968.
Statistical analyses
The primary statistical analysis was Kaplan-Meier survival curves based on EuroSCORE 0-4, 5-9 or >9. Detailed statistical analysis was primarily on low-risk patients (EuroSCORE 0-4). Categorical variables were analysed using the χ 2 -test, while Analysis of variance (ANOVA) ANOVA was used for comparisons between subgroups. Furthermore, we used model-based Poisson regression analysis with robust error variance to estimate adjusted ( patient and procedure factors: age, sex, diabetes (medical treatment), patient-related, cardiac-related and surgery-related EuroSCORE variables; perioperative factors: re-operation due to bleeding, postoperative dialysis (new), perioperative MI, perioperative use of Inotropics together with transfusion of blood, FFP and PLT) risk ratios to identify independent factors with impact on longterm survival. Analyses were performed with MedCalc® software version 11.5.1 (Mariakerke, Belgium). A probability value of <0.05 was used to define statistical significance.
RESULTS
The total cohort identified was 25 117 patients. A flow chart of all exclusions is shown in Fig. 1 . Except for 85 non-Danish residents with invalid CPR number all outcomes were accounted for. Patients subjected to CABG, AVR, MVR, CABG + AVR and CABG + MVR were identified. All missing information on transfusion in WDHR was obtained from Danish Transfusion Registry giving a cohort of 20 001 with no missing data. Patients were divided into three groups defined by EuroSCORE (Fig. 1) . Selected demographic parameters are shown in Table 1 .
The association between residual EuroSCORE (EuroSCORE minus age score), age and transfusion of RBC is shown in Table 2 . The correlation between residual EuroSCORE and RBC transfusion was highly significant increasing from 26.6% in patients with residual EuroSCORE 0-2 to 85.4% in patients with residual EuroSCORE greater than 11 (P < 0.0001, χ 2 -test). Further, there was a correlation between increasing residual EuroSCORE and increasing volume transfused (ώ = 0.123, P < 0.0001). Although the number of patients receiving RBC increased with age (P < 0.0001, χ 2 -test), the mean volume of RBC was not correlated to increasing age (ώ = 0.014, P = 0.243).
The Kaplan-Meier survival plot for patients undergoing simple procedures and with EuroSCORE 0-4 ( Fig. 2a) demonstrates a significantly (P < 0.0001) lower survival rate for those receiving RBC (0.637 vs. 0.745) and a hazard ratio of 1.68. For patients with EuroSCORE 5-9 (Fig. 2b) , the difference, although significant (P < 0.0001), was less being 0.373 vs. 0.436 and a hazard ratio of 1.32. Patients with EuroSCORE >9 (Fig. 2c) showed no significant difference in mortality between patients with or without RBC transfusion.
Of the transfused patients overall 55.0% received 1-2 units, 24.6% received 3-4 units, 10.1% 5-6 units and 10.3% more than 6 units ( Table 3 ). The fraction receiving more RBC units increased with a higher EuroSCORE (P < 0.0001, χ
The impact of number of transfused units is shown in Fig. 3 . The Kaplan-Meier survival plot demonstrates significant difference between no transfusion and any group of units transfused (P < 0.0001). The long-term survival probability rate for patients receiving 1-2 units was 0.631 vs. 0.758 in patients not receiving RBC. Additionally, the difference between 1-2, 3-4 and 5-6 units of RBC is marginal, while patients transfused with more than six units showed a long-term survival probability rate of 0.525.
Transfusion of RBC in low-risk patients is an independent risk factor for long-term mortality as demonstrated in Table 4 showing adjusted odds ratios (OR) for selected perioperative variables. Age, EuroSCORE patient-and cardiac factors, need for dialysis, perioperative MI, use of perioperative inotropics and RBC transfusion all had independent negative impact on longterm survival, while female sex, valve procedure and transfusion of PLT had independent positive impact. The only factor with higher impact on long-term mortality was the need for postoperative dialysis.
DISCUSSION
The analysis shows that low-risk patients have significantly higher long-term mortality when receiving RBC during cardiac surgery compared with patients who do not receive transfusions (Fig. 2a) . The risk is reduced with increased EuroSCORE, and in patients with EuroSCORE >9 RBC transfusion has no impact on long-term survival (Fig. 2c) . Previous studies have included patients dying within 30 days of surgery (4, (6) (7) (8) (9) (10) . However, causes of death within the first 30 days after cardiac surgery are often a mixture of surgical challenges, reduced cardiac function, infection, sepsis and coagulopathy, which makes it difficult to extract solely the impact of transfusion. Therefore, we excluded early mortality in our final analysis. The number of patients dying within 30 days of surgery was relatively low and therefore have little impact on the overall mortality.
In previous studies, after extracting the 30-day mortality, a relatively small (4, 9-10) or no (5, 7-8) impact of blood transfusion is seen on long-term survival. Our data show a difference in mortality of 10.8% in low-risk cardiac patients during more than 12 years of observation (Fig. 2a) . The adjusted OR of the low-risk cohort (EuroSCORE 0-4 and CABG, AVR and MVR procedures) demonstrates that transfusion of blood is an independent risk factor associated with higher long-term mortality. That the effect of RBC on long-term mortality was lower with higher EuroSCOREs can readily be explained primarily with increasing age, as the average age of EuroSCORE 0-4 patients was 61.3 ± 9.0 compared with 71.7 ± 8.2 for EuroSCORE 5-9 and 74.3 ± 8.9 for EuroSCORE >9. With more than 12 years of observation time this would exceed the average living age in Denmark for the last two groups. When considering EuroSCORE >9, the average age and the fact that the overall mortality for patients below 70 years of age was 25.0% in patients with EuroSCORE >9 compared with 11.7% patients with EuroSCORE 0-4 further imply that those patients had higher general impact of comorbidity which influence mortality more than RBC transfusion.
Our data showed that the number of patients receiving RBC increased with age, while the average transfused volume was not correlated to increasing age. This was in disparity to the correlation to residual EuroSCORE (EuroSCORE minus point for age and sex) where also a higher volume was seen with increasing score.
The finding that female sex has a positive impact on the longterm survival is in variance with a general perception and the EuroSCORE. However, the EuroSCORE only handle 30-day mortality and further due to our EuroSCORE grouping in the analysis females are bound to have a lower age as the one point for female sex is equivalent with up to five years older age. Although the average age for females was higher in the total database, the age was 1.4 year lower in the EuroSCORE 0-4 group compared with men, which might at least partly explain the difference.
In general, this study focused on allogeneic RBC transfusion, but other blood products, i.e. PLT and FFP, may also be associated with adverse outcomes including severe infections. However, the results in the literature are conflicting. Most studies suggest that transfusion with PLT and FFP does not confer an increased risk of morbidity or mortality [13] [14] [15] , which is in accordance with this study where we found no impact of FFP on long-term survival (Table 4) . PLT dysfunction is an important cause of excessive bleeding after cardiac surgery [13, [16] [17] [18] [19] . Disparate findings have been reported regarding whether PLT transfusions are associated with adverse outcomes after cardiac surgery [13, 19] . All studies were with short postoperative observation time. The positive impact on long-term survival found in this study is not readable and explainable. However, as a reduced effect of PLT is known after cardiac surgery [17, 18] , the transfusion of PLT could theoretically lead to lower bleeding and thus lower transfusion need. We were not able to demonstrate postoperative bleeding as a trigger for PLT infusion is excessive bleeding. However, the hypothesis is supported by the fact that overall 6.1% of patients received PLT transfusion without RBC transfusion. Transfusion of more than six units and most likely 5-6 units as well has undoubtedly been a life-saving treatment during the perioperative phase. In elderly patients with low preoperative haemoglobin levels, the transfusion of 3-4 units of RBC may be inevitable. Noteworthy is that more than half of the patients only received 1-2 units, a practice that might be argued and is controversial as it seems to have the same negative impact on the long-term survival. Although a recent study [5] only found increased mortality when receiving more than 6 units, our data suggest that the risk up to 6 units is the same and further increased when transfusion exceeds 6 units (Fig. 3) and it can be questioned whether this strategy of transfusing few RBC units really be considered the best clinical practice?
Not all associations are causal and no randomized controlled studies have been carried out in order to evaluate the possible causal relationship between allogeneic blood transfusion and late postoperative mortality in cardiac surgery. A possible explanation for a causal association between transfusion and mortality may in some way include described functional and structural changes that RBC undergoes during storage [20] . Furthermore, the immune modulation induced by allogeneic blood transfusion may play a role [21] . However, the precise mechanism accounting for adverse outcomes following transfusion in cardiac surgery remains to be proved.
Randomized controlled studies in cardiac surgery indicate that transfusion with white blood cell (WBC)-reduced RBC units, compared with standard buffy-coat-reduced RBC transfusion, results in lower postoperative infection and mortality rates [22] [23] [24] , while other studies found no such effect [4, 25] . This difference between studies may be a consequence of different amounts of WBCs in the non-WBC-reduced blood products. In the present study, we did not differentiate between transfusions with different WBC contents.
Since there is no clear evidence to support the view that transfusion actually improves patient outcome in all situations during cardiac surgery, surgeons and anaesthesiologists need further information from studies on transfusion outcome to balance the potential benefits and risks of allogeneic transfusion.
Strength and limitations of study
It is important to consider whether these observational findings could have arisen because of confounding. Transfused patients were evaluated by EuroSCORE less healthy before their operations and may have had poorer outcomes for this reason rather than because they were transfused. Our data management might argue against this. First, the material was divided on EuroSCORE narrowing both different factors and to some extent age that influence results: Secondly, the cohort for final analysis only contains well-defined operative procedures and thirdly the cohort does not contain patients with missing survival outcome data.
Exposures and outcomes may have been misclassified for some patients (a potential problem with routine data sets), but no reason exists to suspect that misclassification would be differential for patients who were transfused and not transfused. Using routine databases minimizes susceptibility to information bias because data were collected independently of the researchers. Non-differential misclassification would cause observed associations to be underestimated. Cardiac surgery has, by far, the greatest risk of RBC transfusion compared with other kinds of surgery and by excluding re-operations and multiple entries in our database we have, to some extent, reduced the confounder of previous transfusions. The primary limitation is that patients during the observation period may have undergone other noncardiac surgical procedures and may for this or other reasons have received blood products, which may have an impact on the final outcome. However, the number of patients in the cohort is so large that this should not influence the overall findings.
A major limitation is that we have not been able to include information on haemoglobin neither pre-nor postoperatively and thus we have no information whether the patients with only transfusion of 1-2 units could be avoided. However, very low haemoglobin levels are very rarely seen preoperative in Denmark and thus we believe that transfusion is seldom guided by preoperative low haemoglobin, although it might influence perioperative transfusion.
Several strengths of the study offset these potential limitations. The study included an entire cohort of consecutive cardiac surgery patients. As registration in the WDHR has been compulsory since 1999, the risk of missing patients or procedures is considered extremely low. We were able to obtain any missing transfusion data from an entirely independent source, which is widely regarded as having extremely high quality. This together with the unique Danish Civil Registration System which sequentially counts the Danish population ensures that all procedures and outcomes are accounted for.
Despite these strengths, the results should be interpreted with caution. The study was observational and, although we considered a wide range of covariates during design and analysis, we cannot exclude the possibility that residual confounding due to the use of crude variables (e.g. presence of comorbidities) or unknown/unmeasured prognostic factors, including lifestyle factors, may have confounded the results.
CONCLUSION
Long-term follow-up on low-risk patients undergoing simple standard cardiac surgery demonstrates a more than 10% higher mortality in patients receiving perioperative RBC transfusion. Our data revealed that even transfusion of 1-2 units of RBC, the indication of which might be challenged, carries a substantial risk of increased long-term mortality.
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